These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8099194)

  • 1. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
    Malmberg A; Jackson DM; Eriksson A; Mohell N
    Mol Pharmacol; 1993 May; 43(5):749-54. PubMed ID: 8099194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.
    Mohell N; Sällemark M; Rosqvist S; Malmberg A; Högberg T; Jackson DM
    Eur J Pharmacol; 1993 Jul; 238(1):121-5. PubMed ID: 8405075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides.
    Malmberg A; Mohell N
    J Pharmacol Exp Ther; 1995 Aug; 274(2):790-7. PubMed ID: 7636742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells.
    McAllister G; Knowles MR; Ward-Booth SM; Sinclair HA; Patel S; Marwood R; Emms F; Patel S; Smith A; Seabrook GR
    J Recept Signal Transduct Res; 1995; 15(1-4):267-81. PubMed ID: 8903944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
    Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
    Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P; Guan HC; Van Tol HH; Niznik HB
    Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
    Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
    Van Tol HH; Bunzow JR; Guan HC; Sunahara RK; Seeman P; Niznik HB; Civelli O
    Nature; 1991 Apr; 350(6319):610-4. PubMed ID: 1840645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors].
    Futamura T; Ohashi Y; Yano K; Takahashi Y; Haga K; Fukuda T
    Nihon Yakurigaku Zasshi; 1996 May; 107(5):247-53. PubMed ID: 8690306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
    Seeman P; Tallerico T
    Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding.
    Jerning E; Malmberg A; Mohell N
    J Recept Signal Transduct Res; 1995; 15(1-4):503-15. PubMed ID: 8903960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.